74 results about "Cartilage lesion" patented technology

The present application relates to chondrocyte compositions and kits comprising morselized cartilage tissue particles and a biodegradable matrix. Applications and methods of using the chondrocyte composition for cartilage grafts, repairing cartilage injuries and defects, and joint repair are provided.

The invention provides a mechano-electric coupling hydrogel microsphere with stable mechanical property and low loss transduction as well as a preparation method and application thereof, and belongs to the technical field of tissue engineering bioremediation materials. According to the invention, supramolecular engineering and microfluidic technologies are utilized, and a slip ring structure polyrotaxane and conductive polypyrrole network is introduced to construct stress-electric coupling hydrogel microspheres. The molecular slippage mechanism of the slip ring structure stores and releases mechanical energy to reduce mechanical loss, and the conjugated pi-electron movement in the conductive network improves the electron transfer efficiency in the microsphere, so that the loss in stress-electricity conversion is reduced for the first time. Compared with the traditional piezoelectric hydrogel microspheres, the stress-electric coupling efficiency of the low-dissipation microspheres is improved by 2.3 times, and the energy dissipation rate is reduced to 43%. The mechano-electric coupling hydrogel microspheres can reduce cartilage injury of rats, improve behavior results and promote treatment of osteoarthritis by recovering low-loss transduction between tissues.

The invention belongs to the field of biological medicines, and particularly relates to application of loganic acid in preparation of a medicine for treating arthritis. Specifically, through experimental research of a collagen-induced arthritis mouse model, the loganin acid is found to be capable of remarkably relieving arthritis symptoms, relieving joint swelling, synovitis and cartilage injury in a dose-dependent manner, and reducing the levels of proinflammatory factors TNF-alpha and IL-6 in plasma. By further combining 16S rRNA sequencing analysis, the loganic acid can remarkably regulate the intestinal microbiota structure of arthritis mice, increase the abundance of Lactobacillus murinus in the intestinal tract and promote the generation of tryptophan metabolite indole-3-acetic acid, so that the effect of resisting rheumatoid arthritis is achieved through an intestinal flora dependent mechanism. Therefore, the invention provides a new application of loganin acid in preparation of a medicine for treating arthritis, and the compound has further research and application values as a potential small molecule medicine.

The invention discloses injectable hydrogel for cartilage injury repair and a preparation method of the injectable hydrogel. The gel is prepared by crosslinking 3 to 4 parts of recombinant III type humanized collagen-sodium hyaluronate gel particles, 0.5 to 1 part of thrombin solution and 4 to 6 parts of fibrinogen solution. The recombinant III type humanized collagen-sodium hyaluronate-thrombin-fibrinogen gel for injection, prepared by the preparation method disclosed by the invention, has the advantages of high elastic modulus, good biocompatibility, good needle passing performance and long in-vivo degradation period. Particularly, the recombinant III type humanized collagen-sodium hyaluronate-thrombin-fibrinogen gel for injection prepared by the invention can effectively promote regeneration of cartilage tissues, and is an innovative cartilage repair gel.

The invention relates to the technical field of medicines, foods and health-care products, in particular to application of morusin in preparation of a product for treating osteoarthritis. A hydrogen peroxide induced chondrocyte in-vitro model and a D-galactose subcutaneous injection osteoarthritis animal model are used for screening and evaluating the morusin, and it is found that the morusin has the obvious effects of relieving articular cartilage injury, enhancing articular cartilage toughness, delaying the course of osteoarthritis and the like. Wide application prospects are realized in the aspect of preparing products for treating osteoarthritis.

The present invention relates to the technical field of medical equipment, and discloses a cartilage sliding wear modeling device, including a moving assembly, including a moving part, including a friction head, a moving rod, a moving block and a push rod, wherein the moving rod is fixed to one side of the friction head, the moving block is fixed to one end of the moving rod, the push rod is hinged to one side of the moving block, and an adjustment assembly is arranged on the push rod, including an adjustment block, a threaded rod, a knob and a drive block, the adjustment block is hinged to one end of the push rod, the threaded rod is plugged into one side of the adjustment block, the threaded rod and the adjustment block are threadedly connected, the knob is fixed to one end of the threaded rod, and the drive block is arranged on one side of the knob. The beneficial effects of the present invention are: the device size should be small, suitable for laboratory environments and small experimental animals, and quantitative intervention can be achieved by accurately controlling the friction pressure, single distance, etc., to simulate different degrees of cartilage damage.

The invention provides a traditional Chinese medicine composition, a traditional Chinese medicine preparation, a preparation method and application, and particularly belongs to the technical field of traditional Chinese medicine. The invention provides a traditional Chinese medicine composition. The traditional Chinese medicine composition comprises the following components in parts by weight: 20-50 parts of parched white peony root, 8-15 parts of pawpaw, 10-20 parts of radix clematidis, 20-40 parts of caulis spatholobi, 5-12 parts of honey-fried licorice root, 10-20 parts of fructus broussonetiae, 10-20 parts of radix cyathulae and 5-12 parts of cassia twig. The traditional Chinese medicine composition has great potential in the aspects of treating kOA and inhibiting osteophyte formation, and can be used for improving kOA cartilage injury. Through in-vitro experiments, network pharmacology and in-vivo experiments, the curative effect of XBD in treating kOA and the effect of XBD in inhibiting osteophyte formation are verified, it is proved that XBD has a regulation effect on cartilage degeneration and osteophyte formation, and an important thought is provided for developing innovative drugs with cartilage protection and abnormal osteophyte formation inhibition functions.

The invention relates to the technical field of biological medicines, and particularly discloses application of emetine hydrochloride in preparation of a medicine for treating osteoarthritis. A cell test shows that the chondrocyte activity can be remarkably improved by an epecinol hydrochloride alkaline solution; animal model tests show that the epecinol hydrochloride alkali solution can maintain the steady state of chondrocyte metabolism, significantly reduce the cartilage injury degree of osteoarthritis mice and relieve osteoarthritis, and provides a new way for improving the osteoarthritis condition. The chemical structural formula of the emetine hydrochloride is shown in the specification.

The present invention provides a mechanoelectrically coupled hydrogel microsphere with stable mechanical properties and low-loss transduction, as well as a preparation method and application thereof, belonging to the technical field of tissue engineering biorepair materials. The present invention utilizes supramolecular engineering and microfluidics technology to introduce a slip-ring structured polyrotaxane and a conductive polypyrrole network to construct stress-electrically coupled hydrogel microspheres. The molecular slip mechanism of the slip-ring structure stores and releases mechanical energy, reducing mechanical losses, while the conjugated π-electron movement in the conductive network improves the efficiency of electron transfer inside the microspheres, thereby reducing the losses in stress-electric conversion for the first time. Compared with traditional piezoelectric hydrogel microspheres, the mechanoelectrically coupled hydrogel microspheres of the present invention have a stress-electric coupling efficiency of 2.3 times higher than that of traditional piezoelectric hydrogel microspheres, and the energy dissipation rate is reduced to 43%. The mechanoelectrically coupled hydrogel microspheres can alleviate cartilage damage in rats, improve behavioral outcomes, and promote the treatment of osteoarthritis by restoring low-loss transduction between tissues.

The invention discloses application of guaiacol in treatment of rheumatoid arthritis, and particularly relates to application of guaiacol in preparation of drugs for treating rheumatoid arthritis. Cell experiments prove that guaiacol can effectively down-regulate expression of proinflammatory factors in macrophages and up-regulate expression of anti-inflammatory factors, and has remarkable anti-inflammatory activity; animal experiments show that the guaiacol effectively relieves rheumatoid arthritis model mouse diseases, and the specific manifestation is that the guaiacol obviously relieves the mouse claw swelling degree, reduces the arthritis disease score, obviously improves joint inflammatory cell infiltration, repairs cartilage injury, inhibits osteoclast generation and reduces the number of joint apoptotic cells; meanwhile, the level of proinflammatory factors in serum of mice can be effectively reduced, and the level of proinflammatory repair factors can be up-regulated. The invention proves that guaiacol has a definite curative effect on rheumatoid arthritis, good biological safety and no obvious side effect, provides a new effective active component for the treatment of rheumatoid arthritis, and has a good prospect of being developed into the medicine for treating rheumatoid arthritis.

The present invention discloses the use of Histatin-1 polypeptide in promoting cartilage regeneration or repair. By preparing a combined reagent composed of Histatin-1 polypeptide, a biological scaffold material, etc., mainly by loading linear Hst1 on gelatin methacrylate, it is used for cartilage injury repair or promoting cartilage growth. At the same time, the use of Histatin-1 polypeptide in promoting the expression of one or more of the bone differentiation indicators, including collagen fibers, glycosaminoglycans, type II collagen, and aggrecan, is also disclosed.

The invention provides an application of an Akt pathway activator in treatment of cartilage injury and systemic reaction caused by joint hemorrhage. Knee joint hemorrhage modeling is carried out on mice and pigs; it is found that the Akt pathway activator sc79 and vitamin E have remarkable curative effects in treatment of cartilage injury, systemic reaction, liver injury and peripheral blood inflammation caused by joint bleeding, and a new target and a new treatment means are provided for prevention and treatment of joint bleeding.

The present invention relates to a pharmaceutical composition for treating cartilage damage diseases, comprising, as an active ingredient, magnetic nanoparticle-embedded nasal septal chondrocytes , and establishes a method for embedding magnetic nanoparticles into nasal septal chondrocytes and a method for preparing spheroids by culturing magnetic nanoparticle-embedded nasal septal chondrocytes. It was identified that the magnetic nanoparticle-embedded nasal septal chondrocytes prepared by the method of the present invention and spheroids prepared therefrom exhibit cartilage damage treatment activity while maintaining mobility in a magnetic field. In addition, since the activity is maintained even if spheroids are prepared by mixing magnetic nanoparticle-embedded nasal septal chondrocytes and nasal septal chondrocytes, the present invention can be effectively used as a composition for treating cartilage damage diseases that has an excellent therapeutic effect without causing side effects by having a significantly reduced addition ratio of the magnetic nanoparticles.

Hydrolyzed collagen compositions are described which are used for treatment of impaired cartilage or to prevent damage to healthy cartilage. These compositions function across multiple cartilage components and structures. Oral, topical, or cartilage-site delivery of the compositions to cartilage may be via liquid, gel, powder, or sheet form. Additionally, the hydrolyzed collagen composition may be applied as a coating on a medical device.

This invention discloses a method for preparing a 3D-printed hydrogel scaffold for cartilage repair, comprising: providing methacrylamide chitosan; providing 2-([1,1-biphenyl]-4-ylcarbamoyl)benzoic acid@polylactic acid-glycolic acid copolymer microspheres; obtaining a 3D-printed bio-ink for cartilage repair using methacrylamide chitosan, 2-([1,1-biphenyl]-4-ylcarbamoyl)benzoic acid@polylactic acid-glycolic acid copolymer microspheres, recombinant collagen CF-1552, and lithium magnesium silicate as main raw materials; and obtaining a 3D-printed bio-ink for cartilage repair using the 3D-printed bio-ink for cartilage repair as a raw material to obtain a 3D-printed hydrogel scaffold for cartilage repair. This 3D-printed hydrogel scaffold has advantages such as antibacterial properties and the ability to promote the differentiation of human bone marrow mesenchymal stem cells (hBMSCs) into chondrocytes, and can be used for cartilage repair, potentially bringing new curative opportunities for cartilage injury diseases.

The invention relates to the technical field of cell preparations, in particular to a method for rapidly evaluating the repairing function of cartilage cells on cartilage injury at low cost, which comprises the following steps: constructing a cartilage injury model by adopting pig knee and femoral joint cartilage tissues, inoculating cell spheres formed by the to-be-evaluated cartilage cells to an injury part of the cartilage injury model, and evaluating the cartilage injury part of the cartilage injury model. And transplanting the cartilage cells into an experimental animal body, and evaluating the repair function of the cartilage cells according to the repair condition of the cartilage injury model. The method provides a systematic scheme for evaluating the repairing function of the cartilage cells, has the advantages of simplicity in operation, short time consumption, low cost, high stability and the like, and provides an effective method for evaluating the functions of the cartilage cells and screening and evaluating the functions of cells such as induced pluripotent stem cells with cartilage injury repairing potential; the method has a good application prospect in development of cell preparations for cartilage injury repair.

The invention relates to an Apt / DNA-PPK hydrogel sustained-release system as well as a preparation method and application thereof. The Apt / DNA-PPK hydrogel sustained release system is characterized in that an aptamer (Apt-DNA) DNA hydrogel (Apt-DNA) with a stem cell capturing function is combined with dopamine nanoparticles with an NIR response release function. Wherein the premix solution of the Apt / DNA-PPK hydrogel sustained release system contains Apt-DNA, PDA (Personal Digital Assistant), KGN (Kinyl Glycol Nitride) and PEI (Polyether Ionium). Compared with the prior art, the Apt / DNA-PPK hydrogel sustained-release system disclosed by the invention has the advantages that free BMSCs (bone marrow mesenchymal stem cells) in the joint are captured through the cell capturing function of the Apt 19S. Meanwhile, under the irradiation of NIR, the Apt / DNA-PPK hydrogel releases the loaded KGN, and the KGN differentiates the BMSCs captured by the hydrogel into cartilage cells, so that the problem of cartilage injury in the early stage of osteoarthritis is solved, and an innovative strategy and material selection are provided for tissue engineering.

The utility model provides a composite cartilage scaffold. The composite cartilage scaffold comprises a cartilage scaffold layer, a calcification scaffold layer and a subchondral bone scaffold layer which are sequentially stacked and arranged from top to bottom, a plurality of first immersion channels communicated with each other are arranged in the cartilage stent layer and the calcification stent layer, a plurality of first immersion holes are formed in the top of the cartilage stent layer, a plurality of second immersion holes are formed in the side wall of the calcification stent layer, and the first immersion holes and the second immersion holes are communicated with the first immersion channels. Before an operation, the cartilage scaffold layer and the calcification scaffold layer are soaked with cartilage cells, and the cartilage cells are rapidly immersed into the first immersion channel through the first immersion hole and the second immersion hole, so that the cartilage scaffold layer and the calcification scaffold layer can absorb more sufficient cartilage cells, and the cartilage cell content of the scaffold is increased; the secretion of cartilage extracellular matrix is better promoted, the extension of cartilage cells and the coupling between the cartilage cells and in-situ cartilage are facilitated, and the repair of cartilage injury is further promoted.

The invention belongs to the technical field of biological medicine, and discloses application of miRNA Let-7a-5p in a medicine for promoting cartilage formation, the invention provides the effect of miRNA let-7a-5p in cartilage formation / generation for the first time, and experiments prove that miRNA let-7a-5p can remarkably promote cartilage cell proliferation, enhance the activity of cartilage cells and remarkably improve matrix secretion of cartilage cells, so that the effect of promoting cartilage formation / generation is achieved. The expression of type II collagen is increased (the type II collagen is the main component of the cartilage matrix). Meanwhile, the miRNA let-7a-5p can also regulate other genes (such as NBL1 and DUSP7 genes) to inhibit cartilage ossification, and is expected to be applied to cartilage injury repair and osteoarthritis treatment, cartilage regeneration promotion and cartilage injury repair.

The invention relates to the technical field of biological medicines, and particularly discloses application of adenosine monophosphate in preparation of a medicine for treating osteoarthritis. Cell tests show that the adenosine monophosphate solution has an inhibition effect on cartilage cell activity; animal model tests show that the adenosine monophosphate normal saline solution can remarkably relieve the cartilage injury degree of osteoarthritis mice and relieve osteoarthritis, and a new way is provided for improvement of osteoarthritis conditions. The chemical structural formula of adenosine monophosphate is shown in the specification.

The present invention relates to a blunt-tipped cartilage filling device and a surgical vehicle with the device. The device comprises a hard hollow rod, a blunt-tipped scraper and a handle. A hollow channel is arranged at the center of the hard hollow rod. The blunt-tipped scraper is fixedly arranged at the first end of the hard hollow rod; the blunt-tipped scraper comprises a blunt-tipped flattening disk and a through hole arranged at the center of the blunt-tipped flattening disk; the handle is sleeved and fixed on the hard hollow rod, and the second end of the hard hollow rod passes through the handle; an inlet is opened axially at the second end, and the inlet is used to communicate with an injection device, so that the separated and collected cartilage tissue of the patient himself or the cartilage tissue cultured in a laboratory is directly filled into the cartilage injury site of the patient through the inlet at the second end of the hard hollow rod, the hollow channel of the hard hollow rod and the through hole at the center of the blunt-tipped flattening disk of the blunt-tipped scraper in sequence; the blunt-tipped scraper is used to scrape and compact the cartilage tissue filled into the cartilage injury site of the patient.

The invention belongs to the technical field of biological medicines, and particularly relates to application of xanthosine monophosphate in preparation of a medicine for treating osteoarthritis. The molecular formula of the xanthosine monophosphate is C10H13N4O9P, and the structure of the xanthosine monophosphate is shown in the specification. Research results show that the flavin monophosphate solution has an inhibition effect on cartilage cell activity; animal model tests show that the flavin monophosphate normal saline solution can remarkably relieve the cartilage injury degree of osteoarthritis mice and relieve osteoarthritis, and a new way is provided for improvement of osteoarthritis conditions. .

The invention discloses a mesenchymal stem cell compound preparation for treating cartilage injury, and belongs to the technical field of cell biology. The composite preparation consists of human umbilical cord mesenchymal stem cells (hUC-MSC) subjected to specific pretreatment and a pharmaceutical carrier. The pretreatment method sequentially comprises the following steps: carrying out low-oxygen pretreatment on the hUC-MSC; then, carrying out pretreatment on a ferroptosis inhibitor Ferrostatin-1 under a low-oxygen condition; and finally, carrying out icariin pretreatment under a normal oxygen condition. The unique triple pretreatment strategy generates a remarkable synergistic effect, and can greatly improve the survival rate and the function maintenance capability of the hUC-MSC in the cartilage injury inflammatory microenvironment. Experimental results prove that the preparation can significantly inhibit collagen degradation and promote cartilage matrix regeneration, and the treatment efficiency of stem cell transplantation and the repair effect of cartilage injury are effectively improved.

This invention provides a stress-triggered selective targeting hydrogel microsphere, its preparation method, and its application, belonging to the field of biomedical technology. The core of this invention is the "stress-triggered charge reversal" mechanism. It utilizes the interaction between weakly cross-linked disulfide bonds broken under stress and "charge reversal" messenger molecules to achieve "charge reversal" of nanoparticles under stress. A dual-network hydrogel microsphere system is prepared using microfluidic technology to achieve bearing lubrication and stress relaxation within the joint cavity. Stress-triggered charge reversal is achieved at stress-overloaded cartilage lesions, imparting a positive charge to the drug-loaded nanoparticles within the hydrogel microspheres. This significantly enhances the ability of the drug-loaded nanoparticles to penetrate deep into the cartilage matrix and target chondrocytes for drug release under the guidance of the charge. This enables the selective and targeted release of appropriate drug concentrations to deep-seated chondrocytes in pathological microenvironments induced by different stress intensities, achieving highly effective and low-toxicity treatment of osteoarthritis.

The present application relates to a kind of polypeptide for cartilage repair and its composition and application, belong to bone injury repair technical field.The polypeptide is polypeptide PG155, and the experimental results of the present application show that it can repair cartilage damage caused by osteoarthritis to some extent.Further research shows that the special exosome (PG155-Exo) produced by polypeptide PG155 pretreatment bone marrow mesenchymal stem cells combined with polypeptide PG155, can significantly enhance the therapeutic effect, and show obvious synergistic effect.This synergistic effect makes the cartilage repair effect significantly better than single therapy, and provides more efficient treatment scheme for osteoarthritis patients.

The invention provides a method for treating arthritis by using mesenchymal stem cells subjected to limited induction in vitro. Osteoarthritis is a common joint degenerative disease and is mainly characterized by cartilage injury and inflammatory response. The traditional treatment method is difficult to realize cartilage regeneration, but mesenchymal stem cells (MSC) show a prospect in joint repair due to multidirectional differentiation potential and immunomodulatory effect. According to the invention, bergenin (KGN) is utilized in vitro to induce MSC to differentiate into chondrocytes, so that the chondrogenic ability of the cells is enhanced. The inducible MSC is injected into a rat gonitis model, cartilage repair is remarkably promoted, and inflammation is reduced. Experimental results show that the method can effectively relieve arthrocele, improve the motion function and reduce the pain sensitivity. The invention not only improves the treatment effect of MSC, but also provides a safe and effective new approach for treating arthritis, and has important clinical application value.

This invention relates to a method for constructing a humanized pig model of type II collagen and its application, belonging to the field of gene modification technology. The invention first provides a CRISPR-Cas9 system for targeted editing of the porcine type II collagen α1 gene. Using CRISPR / Cas9-mediated homologous recombination, the porcine COL2A1 gene is orally replaced with the human COL2A1 gene. Then, using somatic cell cloning technology, a humanized pig model of type II collagen is constructed, allowing the pig to produce cartilage tissue more similar to that of humans, reducing post-transplant immune rejection. This is expected to fundamentally solve the problem of human cartilage tissue shortage and has significant implications for the treatment of articular cartilage damage, providing a better and more suitable transplant material for the treatment of articular cartilage damage.

The invention relates to application of platelets modified by matrix metalloproteinase 13 in prevention and treatment of arthritis. Specifically, the invention provides a platelet complex, which is characterized by comprising platelet cells, a chemical linker element and a specific protein, wherein the platelet cells are linked to the specific protein through the chemical linker element, and the specific protein comprises an antibody targeting a cartilage injury specific expression molecule. The platelet complex (platelet at MMP13) disclosed by the invention is combined with MMP13 released by active targeting OA cartilage injury lesion sites, and cartilage repair and regeneration can be promoted, so that the effect in drugs for preventing and / or treating OA can be achieved.

The invention relates to regenerated cartilage based on hydrostatic pressure stimulation and a preparation method and application thereof. The method comprises the following steps: inoculating cells on a porous hydrogel scaffold, placing the porous hydrogel scaffold in a culture medium, performing pressure stimulation by adopting a hydrostatic pressure bioreactor, and performing in-vitro culture for a period of time to obtain the regenerated cartilage based on hydrostatic pressure stimulation. Key mechanical sensitive channels TRPV4 and PIEZO1 are up-regulated through hydrostatic pressure stimulation, a Ca < 2 + > dependent TRPV4 / PIEZO1-Ca < 2 + >-SOX9 mechanical transduction pathway is activated, cartilage formation is promoted, and hypertrophy and ossification are inhibited. Through verification, the bioreactor system is combined with the porous hydrogel scaffold, has good biocompatibility, controllable pore structure and mechanical property, and is suitable for cartilage cell culture. After in-vitro pre-culture for 4 weeks, the cartilage-like construct subjected to HP pretreatment shows a long-term stable regeneration effect in an animal model (such as a goat), and especially in an in-situ auricle microenvironment, inflammation and heterotopic ossification can be effectively inhibited, and an efficient in-vitro cartilage engineering strategy is provided for repairing of various cartilage injuries.

The present invention relates to a biomaterial comprising: —a membrane wound patch (a), made of a nanofibrous polymeric scaffold, —a hydrogel (b) including autologous or allogenic bone marrow-derived mesenchymal stem cells, and —a bone wound patch (c) being a nanofibrous scaffold made of polymers, wherein said scaffold has a surface coated with an interrupted coating made of multilayered droplets, said multilayered droplets being droplets composed of at least one layer pair consisting of a layer of polyanions and a layer of polycations, and wherein the bone wound patch (c) further comprises a bone growth factor; wherein the hydrogel (b) is included between the membrane wound patch (a) and the bone wound patch (c).